Business
Telix Full Year Results 2025 Investor Webcast Notification
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") advises that it will release its full year results for the period ended 31 December 2025 on Friday 20 February 2026 AEDT (Thursday 19 February 2026 EST).
About this update from Telix Pharmaceuticals Limited
[{"type":"text","content":"MELBOURNE, Australia and INDIANAPOLIS, Feb. 4, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") advises that it will release its full year results for the period ended 31 December 2025 on Friday 20 February 2026 AEDT (Thursday 19 February 2026 EST).","length":294,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Telix Pharmaceuticals Limited)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Telix Pharmaceuticals Limited)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":166,"url":"https://media.zenfs.com/en/prnewswire.com/0260c8b822b865d6e9308370c79e16fb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/pLUSkugjGfNA5e2aFU4CYQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI5MztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/0260c8b822b865d6e9308370c79e16fb","width":400,"height":166}},"href":"https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"An investor webcast and conference call will be held at 9:30 a.m. AEDT, Friday 20 February 2026 (5:30 p.m. EST, Thursday 19 February 2026).","length":139,"tagName":"p"},{"type":"text","content":"Participants can register at the following link: https://edge.media-server.com/mmc/p/famdpwzh","length":93,"tagName":"p"},{"type":"text","content":"About Telix Pharmaceuticals Limited ","length":35,"tagName":"p"},{"type":"text","content":"Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).","length":624,"tagName":"p"},{"type":"text","content":"Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details ...